Hematolymphoid tumors involving the CNS
2025-01-30 Paola Dal Cin, PhD , Scott Ryall, PhD Affiliation1.Brigham and Women's Hospital , Harvard Medical School, Boston , MA (USA)
2.Brigham and Women's Hospital, Harvard Medical School, Boston , MA (USA)
Keywords
CNS CNS lymphomas, CNS-diffuse large B-cell lymphoma, CNS histiocytic neoplasms, rare CNS lymphomasClassification
Definition
Hematolymphoid tumors involving the CNS are cancers arising from a blood cell lineage that develop within the central nervous system (CNS), primarily in the parenchyma and meninges. Critically, the distinction of primary versus secondary manifestations of the tumors is essential for their accurate diagnosis given than virtually all hematolymphoid tumors involving the CNS may also arise in other organs. Collectively, these are the second most frequent primary brain tumors in adults, second only to glioma. 1
The 2021 World Health Organization (WHO) classification of hematolymphoid tumors involving the CNS categorizes tumors into two major groups: i) Lymphomas and ii) Histiocytic Tumors, the former further segregated into “CNS Lymphomas” and “Miscellaneous Rare Lymphomas in the CNS” to permit expansion of the less common CNS lymphoma subtypes. Of primary CNS lymphoma, diffuse large B-cell lymphoma (CNS-DLBCL) is the most common. 2-4 In contrast, histiocytic neoplasms are extremely rare, thought to be a manifestation of their broad clinical spectrum and variable histology. 5
Historically, the genetic underpinnings of hematolymphoid tumors involving the CNS have been largely unexplored due to limited tissue availability and diagnostic ambiguity. However, recent work has begun to uncover the genetic differences between tumors with immense potential to refine and optimize the current diagnostic strategies and identify therapeutic susceptibilities not previously appreciated.
| Hematolymphoid tumors involving the CNS | |
|---|---|
| Lymphomas involving CNS | Genetic marker(s) |
| Primary diffuse large B-cell lymphoma of the CNS (CNS-DLBCL) | CNS-DLBCL are comprised of B cells derived from self-reactive precursor cells confined to the CNS microenvironment. These cells ubiquitously carry rearranged and somatically mutated immunoglobulin (IG) genes. Evidence of ongoing somatic hypermutation is also noted, and expands to multiple gene targets beyond IG, including BCL6, BCL2, MYC, PIM1, PAX5, RHOH, KLHL14, OSBPL10, and SUSD2. 6-8 Translocations involving the IG genes, BCL6, and ETV6 are common, whereas those affecting MYC and BCL2 are rare and absent, respectively. 9-12 Genetic alterations affecting CD79B and MYD88 are frequently observed, while alterations in INPP5D, CBL, BLNK, CARD11, MALT1 (in 43%), and BCL2 are less frequent and are thought to promote proliferation whilst inhibiting apoptosis. 13-20 Cytogenetic analysis also identified recurrent gains of chromosome 18q (including BCL2 and MALT1, chromosome 12, and chromosome 10q. 13 Recurrent losses include chromosome 6 (including HLA-DRB1, HLA-DQA1, and HLA-DQB1), 8q, and 9p ,including CDKN2A/CDKN2B. 13,21-23 Epigenetic studies have identified changes that may potentially impact tumorigenesis including enhancer silence and hypomethylation of DAPK1, CDKN2A, MGMT, and RFC1, although methylation-based classifiers still struggle with differentiating primary and secondary neoplasms. 13,21,24-26 |
| Immunodeficiency-associated CNS lymphomas | Immunodeficiency-associated CNS lymphomas are a rare clinical entitity, typically associated with Epstein-Barr virus (EBV+). These tumors lacked the MYD88, CD79B, and PIM1 missense variants typically associated with CNS-DLBCL as well as copy number losses of CDKN2A or the HLA genes. Rather, they harbored mutations in SOCS1 of the JAK/STAT pathway and mutually exclusive gain-of-function variants in the NOTCH pathway. Copy number gains were enriched on chromosome 11q23.3 and losses of chromosomes 5q and 17q. 27 Other immunodeficiency syndromes including ataxia telangiectasia, Wiskott–Aldrich syndrome, and IgA deficiency as well as other underlying conditions such as systemic lupus erythematosus, Sjögren syndrome, neoplastic diseases, iatrogenic immunosuppression and infectious disorders such as HIV and HTLV may also increase the risk of CNS lymphomas. |
| Lymphomatoid granulomatosis (LYG) | Lymphomatoid granulomatosis (LYG) is a very rare Epstein-Barr virus (EBV)-driven lymphoproliferative disease in which atypical lymphoid cells accumulate within the affected tissue(s). Most often this includes the lungs, but may also arise in the CNS and kidneys, although no clear association between disease grade and dissemination to the CNS has been observed. 28,29 Isolated EBV-negative cases have also been described. 29,30 The underlying genetics of LYG are largely unknown. |
| Intravascular large B-cell lymphoma (IVLBCL) | Intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive cancer primarily affecting the CNS and skin. Diagnosis of IVLBCL is challenging due to variable clinical manifestations and nonspecific laboratory findings and is often made at autopsy due to limited availability of biopsy material. 31 Similar genetic underpinnings to those observed in DLBCL are noted in IVLBCL including mutations in MYD88, CD79B, SETD1B, and HLA-B and rearrangements of CD274/PDCD1LG2 involving the 3' untranslated region, the latter critical for immune evasion. 32,33 |
| Miscellaneous rare lymphomas in the CNS | |
| MALT lymphoma of the dura | MALT lymphoma of the dura are low-grade lymphomas of mucosa-associated lymphoid tissue composed of marginal zone B cells that sometimes present with plasmacytic differentiation. Inactivation of TNFAIP3 is common in cases with plasmacytic differentiation 34, while activating NOTCH2 mutations paired with inactivating TBL1XR1 mutations are common in cases with monocytoid morphology. 34 Cytogenetic studies have identified recurrent gains of chromosome 6p and losses of chromosome 1p. Translocations involving IGH and/or MALT1 are rare. 35-37 |
| Other low-grade B-cell lymphomas of the CNS | Low-grade B-cell lymphoma is exceptionally rare, with most corresponding to extranodal marginal zone lymphoma, small lymphocytic lymphoma, follicular lymphoma or lymphoplasmacytic lymphoma. 37-43 Clonal rearrangements of IGH and/or IGK, loss of heterozygosity on 6q (including the locus for TNFAIP3, and MALT1 rearrangements have been identified in isolated cases, but recurrent events are uncommon.37,44,45 In specimens tested, MYD88 variants were not observed. 37 |
| Anaplastic large cell lymphoma (ALK+/ALK−) | Primary anaplastic large cell lymphoma (ALCL) arising in the CNS is extremely rare. ALK-positive ALCL constitute ~70-80% of ALCL as defined by ALK-positivity via immunohistochemistry and are gentically driven by oncogenic ALK gene fusions, most commonly with NPM1. 46-49 These ALK fusions result in increased ALK expression, leading to aberrant activation of downstream signalling pathways such as RAS/MAPK and JAK/STAT3 and others. 50 ALK-negative ALCL are thought to harbor mutations or fusions in other receptor tyrosine kinase that activate similar signalling pathways to those in ALK-positive ALCL. A single case with an IRF4/DUSP22 rearrangement has been reported. 51 |
| T-cell and NK/T-cell lymphomas | Primary lymphomas of peripheral T-cell lineage in the CNS are rare and mainly classifiesd as peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), but may also include anaplastic large cell lymphoma, and extranodal natural killer (NK)/T-cell lymphoma (ENKTL). 52,53 A genetic study of 18 primary lymphomas of peripheral T-cell lineage identified somatic mutations in 36% of cases, although none were recurrent. These includes mutations in NMT3A, KRAS, JAK3,STAT3,STAT5B, GNB1, and TET2. 52 A more recent study identified additional pathogenic alterations including those in KMT2C, TET2, NRAS and JAK3 as well as homozygous deletions of CDKN2A and CDKN2B. A single ENKTL case harbored mutations in ARID1B, FAS, TP53, BCOR, KMT2C, POT1, and PRDM1. 54 |
| Histiocytic tumors | |
| Erdheim-Chester disease | Erdheim–Chester disease of the CNS or the meninges manifests as widespread infiltrative parenchymal lesions or a meningioma-like mass and can arise throughout the neuroaxis. Genetics alterations primary target the RAS/MAPK pathway and include BRAF p.V600E, or mutations in MAP2K1, KRAS, NRAS, and PIK3CA. 55-59 Other less common genetic events targeting the RAS/MAPK pathway include ARAF mutations or fusions involving BRAF, NTRK1, ALK, or ETV3 fusions. 58,60 |
| Rosai-Dorfman disease | Studies on Rosai-Dorfman disease are lacking and most large scale studies were unsuccessful at identifying a genetic driver of the disease. However, rare instances of BRAF p.V600E, mutations in KRAS, NRAS, ARAF, MAP2K1, and CSF1R have been described. 58,60 Of note, these lesions often have a low proportion of neoplastic cells, likely resulting in underestimations on their genetic underpinnings. |
| Juvenile xanthogranuloma | Juvenile xanthogranuloma of the CNS is a rare condition typically affecting children and adolescents. Mutations in ARAF, KRAS, and NRAS are common, sometimes arising concurrently whereas the frequency of BRAF p.V600E is unknown. 58,60 Mutations of CSF1R and fusions involving NTRK 1/2/3 are more comonly associated with peripheral juvenile xanthogranuloma and suggest a non-CNS origin. |
| Langerhans cell histiocytosis | BRAF p.V600E is noted in ~50% of langerhans cell histiocytosis while additional isolated cases of p.V600D or mutations in ARAF have also been described. 60-64 Cases without alterations in BRAF often contain variant in other RAS/MAPK pathway genes including MAP2K1, NRAS, KRAS, and PIK3CA. 58,60,61,64-66 |
| Histiocytic sarcoma | Histiocytic sarcoma is an extremely rare and aggressive cancer primarily affecting adults. Genetic aberrations, primarily in the RAS/MAPK pathway, have been identified including those in MAP2K1, KRAS, BRAF, NRAS, PTPN11, NF1, and CBL. 60,67,68 In addition, mutations affecting the PI3K/AKT/mTOR pathway have also been noted including those in PTEN, MTOR, PIK3R1, and PIK3CA sometimes co-ocurring with the aforementioned RAS/MAPK variants. 60,67,68 Deletions of CDKN2A and/or CDKN2B have also been described in a subset of cases. Of note, compared to other histiocytic tumors, BRAF p.V600E is rare in histiocytic sarcoma. |
Article Bibliography
| Reference Number | Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|---|
| 1 | 27846613 | 2017 | Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). | Peñalver FJ et al |
| 2 | 36822829 | 2023 | Imaging of Lymphomas Involving the CNS: An Update-Review of the Full Spectrum of Disease with an Emphasis on the World Health Organization Classifications of CNS Tumors 2021 and Hematolymphoid Tumors 2022. | Pons-Escoda A et al |
| 3 | 37706315 | 2024 | Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy. | Roschewski M et al |
| 4 | 39536287 | 2025 | Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma. | Geng H et al |
| 5 | 31950179 | 2020 | Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. | Bhatia A et al |
| 6 | 14592832 | 2004 | Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. | Montesinos-Rongen M et al |
| 7 | 24970810 | 2014 | Mutational analysis of primary central nervous system lymphoma. | Bruno A et al |
| 8 | 25189415 | 2015 | The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. | Vater I et al |
| 9 | 12387458 | 2002 | Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. | Montesinos-Rongen M et al |
| 10 | 18645192 | 2008 | Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. | Cady FM et al |
| 11 | 24061549 | 2013 | Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. | Brunn A et al |
| 12 | 29432597 | 2018 | Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma. | Bruno A et al |
| 13 | 19494841 | 2009 | Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. | Schwindt H et al |
| 14 | 20544211 | 2010 | Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. | Montesinos-Rongen M et al |
| 15 | 22837180 | 2012 | Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. | Gonzalez-Aguilar A et al |
| 16 | 22020631 | 2011 | Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. | Montesinos-Rongen M et al |
| 17 | 23138649 | 2012 | Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. | Montesinos-Rongen M et al |
| 18 | 24013661 | 2013 | High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. | Kraan W et al |
| 19 | 26111727 | 2016 | Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. | Nakamura T et al |
| 20 | 30723112 | 2019 | MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. | Nayyar N et al |
| 21 | 9546285 | 1998 | Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. | Cobbers JM et al |
| 22 | 11071656 | 2000 | Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. | Riemersma SA et al |
| 23 | 25991819 | 2015 | Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. | Braggio E et al |
| 24 | 15327516 | 2004 | Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. | Ferreri AJ et al |
| 25 | 16858686 | 2006 | Epigenetic silencing of multiple genes in primary CNS lymphoma. | Chu LC et al |
| 26 | 30284345 | 2019 | Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas. | Vogt J et al |
| 27 | 37495858 | 2023 | Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas. | Kaulen LD et al |
| 28 | 16100084 | 2005 | Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging. | Patsalides AD et al |
| 29 | 23006954 | 2012 | Lymphomatoid granulomatosis. | Roschewski M et al |
| 30 | 19322520 | 2009 | Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. | Lucantoni C et al |
| 31 | 26918203 | 2016 | Neurologic manifestations of intravascular large B-cell lymphoma. | Tahsili-Fahadan P et al |
| 32 | 33512416 | 2021 | Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. | Shimada K et al |
| 33 | 34724028 | 2022 | Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and Immunohistochemical Study. | Patel N et al |
| 34 | 27248180 | 2016 | The genetic landscape of dural marginal zone lymphomas. | Ganapathi KA et al |
| 35 | 19669212 | 2008 | Extranodal marginal zone lymphoma of the dura mater with IgH/MALT1 translocation and review of literature. | Bhagavathi S et al |
| 36 | 29103980 | 2018 | Extranodal Marginal Zone Lymphoma of the Central Nervous System. | Ayanambakkam A et al |
| 37 | 32318699 | 2020 | Extranodal Marginal Zone Lymphoma of the Central Nervous System Includes Parenchymal-Based Cases With Characteristic Features. | Nomani L et al |
| 38 | 15725082 | 2005 | Low-grade primary central nervous system lymphoma in immunocompetent patients. | Jahnke K et al |
| 39 | 22994302 | 2013 | Central nervous system marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type involving the brain and spinal cord parenchyma. | Ueba T et al |
| 40 | 24729110 | 2014 | Primary low-grade diffuse small lymphocytic lymphoma of the central nervous system. | Aziz M et al |
| 41 | 31426757 | 2019 | Primary central nervous system small lymphocytic lymphoma in the bilateral ventricles: two case reports. | Guo R et al |
| 42 | 34177522 | 2021 | Primary CNS Extranodal Marginal Zone B-Cell Lymphoma: A Case Series of 2 Patients Treated with External Beam Radiation Therapy. | Ariani R et al |
| 43 | 39321755 | 2024 | Intraparenchymal low-grade B-cell lymphomas of the central nervous system: Clinicopathologic and molecular analysis of three cases and a review of the literature. | Dawid de Vera MT et al |
| 44 | 23947787 | 2013 | Primary cerebral low-grade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and "aggregoma": an update on classification and diagnosis. | Skardelly M et al |
| 45 | 27521434 | 2016 | Primary marginal zone lymphoma of the cns presenting as a diffuse leptomeningeal process. | Gazzola DM et al |
| 46 | 30400214 | 2018 | Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. | Huang H et al |
| 47 | 34503168 | 2021 | Clinical Features and Prognostic Factors for Primary Anaplastic Large Cell Lymphoma of the Central Nervous System: A Systematic Review. | Hirano Y et al |
| 48 | 35460414 | 2022 | Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK Positive. | Ahrendsen JT et al |
| 49 | 37655119 | 2023 | ALK-positive anaplastic large cell lymphoma in adults. | Gromowsky MJ et al |
| 50 | 27879258 | 2017 | Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. | Werner MT et al |
| 51 | 34791573 | 2022 | Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement. | Magaki S et al |
| 52 | 26379152 | 2015 | Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis. | Menon MP et al |
| 53 | 26804925 | 2016 | Primary central nervous system gamma delta cytotoxic T-cell lymphoma. | Mooney KL et al |
| 54 | 34980830 | 2022 | Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing. | Yim J et al |
| 55 | 22879539 | 2012 | High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. | Haroche J et al |
| 56 | 24894769 | 2014 | Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. | Hervier B et al |
| 57 | 25150293 | 2014 | Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. | Emile JF et al |
| 58 | 26566875 | 2016 | Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. | Diamond EL et al |
| 59 | 31807955 | 2019 | Erdheim-Chester Disease: a Concise Review. | Papo M et al |
| 60 | 31768065 | 2019 | Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. | Durham BH et al |
| 61 | 20519626 | 2010 | Recurrent BRAF mutations in Langerhans cell histiocytosis. | Badalian-Very G et al |
| 62 | 22996177 | 2013 | Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. | Kansal R et al |
| 63 | 24652991 | 2014 | Somatic activating ARAF mutations in Langerhans cell histiocytosis. | Nelson DS et al |
| 64 | 26461146 | 2015 | Genomic Alterations in Langerhans Cell Histiocytosis. | Rollins BJ et al |
| 65 | 24982505 | 2014 | High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. | Brown NA et al |
| 66 | 25858893 | 2015 | Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. | Héritier S et al |
| 67 | 26582644 | 2016 | Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. | Kordes M et al |
| 68 | 30626916 | 2019 | Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. | Shanmugam V et al |
Citation
Paola Dal Cin, PhD ; Scott Ryall, PhD
Hematolymphoid tumors involving the CNS
Atlas Genet Cytogenet Oncol Haematol. 2025-01-30
Online version: http://atlasgeneticsoncology.org/solid-tumor/209309/hematolymphoid-tumors-involving-the-cns
